High-Flow Nasal Cannula for COVID-19 Patients: A Multicenter Retrospective Study in China.

ABSTRACT: Background: High-flow nasal cannula (HFNC) may help avoid intubation of hypoxemic patients suffering from COVID-19; however, it may also contribute to delaying intubation, which may increase mortality. Here, we aimed to identify the predictors of HFNC failure among patients with COVID-19. Methods: We performed a multicenter retrospective study in China from January 15 to March 31, 2020. Two centers in Wuhan (resource-limited centers) enrolled 32 patients, and four centers outside Wuhan enrolled 34 cases. HFNC failure was defined as the requirement of escalation therapy (NIV or intubation). The ROX index (the ratio of SpO₂/FiO₂ to the respiratory rate) was calculated. Results: Among the 66 patients, 29 (44%) cases experienced HFNC failure. The ROX

SUBMITTER: Duan J 

PROVIDER: S-EPMC8078589 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature